EUVIMEDEUVIMED entdecken
Crossref

Development and characterization of the novel MYD88 mutated, 6q deleted BCWM .2 cell line for Waldenström macroglobulinaemia

Shirong Liu iD, Xia Liu, Choudhury Fabliha Binte Yusuf, Amanda Kofides, Kara M Soroko, Johany Penailillo, Alexa G Canning, Yang Cao, Guang Yang, Lian Xu, Nicholas Tsakmaklis, Hao Sun und 10 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Shirong Liu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Myeloid Differentiation Factor 88, Chromosome Deletion, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Foundation for the National Institutes of Health, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell lines have enabled a comprehensive understanding of disease biology and the advancement of new therapeutics in Waldenström macroglobulinaemia (WM). Herein, we report the development of BCWM.2, a novel WM cell line derived from an untreated symptomatic WM patient. Immunophenotypic and genomic analyses confirmed its origin from primary bone marrow WM cells. Flow cytometry revealed expression of CD19, CD20, CD23, CD38, CD45RA, CD52, immunoglobulin M (IgM) heavy chain and λ light chain on BCWM.2 cells. Whole genome sequencing demonstrated that, unlike BCWM.1, MWCL‐1 and RPCI‐WM1, which harbour MYD88 L265P mutations, BCWM.2 carries MYD88 S243N . BCWM.2 also exhibited hallmark WM genetic aberrations, including 6q deletion and 6p amplification, along with unique mutations in LYN, AKAP9, HDAC5, RUNX3 and SPI1 . BCWM.2 cells exhibited optimal growth when co‐cultured with HS‐5 stromal cells and developed subcutaneous flank masses in all five NOD‐SCID mice, along with measurable serum human IgM levels. BCWM.2 cells also showed remarkable sensitivity to the B‐cell lymphoma 2 inhibitor venetoclax and the Janus kinase 2/Interleukin‐1 receptor‐associated kinase 1 inhibitor pacritinib, underscoring their utility for identification of pharmacologically active agents. BCWM.2 represents a novel myeloid differentiation primary response 88‐mutated, 6q‐deleted cell line with distinct genomic features for in vivo and in vitro studies for WM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaMyeloid Differentiation Factor 88Chromosome DeletionMutationChromosomes, Human, Pair 6HumansMiceAnimalsCell Line, TumorSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

MYD886q deletionBCWM.2CXCR4Waldenström macroglobulinaemiaibrutinib

Substanzen

Myeloid Differentiation Factor 88MYD88 protein, humanSulfonamidesBridged Bicyclo Compounds, Heterocyclicvenetoclax

Autor:innen und Institutionen

  • Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Shirong Liu, Shayna R Sarosiek, Jorge J Castillo, Zachary R Hunter, Steven P Treon

Förderung

  • Foundation for the National Institutes of Health
  • Leukemia and Lymphoma Society

Zitieren

APA

Liu, S., Liu, X., Yusuf, C. F. B., Kofides, A., Soroko, K. M., Penailillo, J., Canning, A. G., Cao, Y., Yang, G., Xu, L., Tsakmaklis, N., Sun, H., Guijosa, A., Guerrera, M. L., Patterson, C. J., Carrasco, R. D., Gokhale, P. C., Sarosiek, S. R., Castillo, J. J., …, & Treon, S. P. (2025). Development and characterization of the novel MYD88 mutated, 6q deleted BCWM .2 cell line for Waldenström macroglobulinaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.20072

Vancouver

Liu S, Liu X, Yusuf CFB, Kofides A, Soroko KM, Penailillo J, et al. Development and characterization of the novel MYD88 mutated, 6q deleted BCWM .2 cell line for Waldenström macroglobulinaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.20072

BibTeX
@article{Liu2025,
  author = {Liu, Shirong and Liu, Xia and Yusuf, Choudhury Fabliha Binte and Kofides, Amanda and Soroko, Kara M and Penailillo, Johany and Canning, Alexa G and Cao, Yang and Yang, Guang and Xu, Lian and Tsakmaklis, Nicholas and Sun, Hao and Guijosa, Alberto and Guerrera, Maria L and Patterson, Christopher J and Carrasco, Ruben D and Gokhale, Prafulla C and Sarosiek, Shayna R and Castillo, Jorge J and Hatcher, John M and Hunter, Zachary R and Treon, Steven P},
  title = {Development and characterization of the novel MYD88 mutated, 6q deleted BCWM .2 cell line for Waldenström macroglobulinaemia},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20072}
}
Kostenlos starten →